Please login to the form below

Not currently logged in
Email:
Password:

Bluebird Bio

This page shows the latest Bluebird Bio news and features for those working in and with pharma, biotech and healthcare.

Europe responding to gene therapy challenge, but picture remains fragmented

Europe responding to gene therapy challenge, but picture remains fragmented

Also addressing the conference separately was Doug Denison, head of global pricing and reimbursement at Bluebird Bio, who was explaining the company's payment by instalment system it is proposing for

Latest news

More from news
Approximately 8 fully matching, plus 32 partially matching documents found.

Latest Intelligence

  • Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

    LentiGlobin (betibeglogene darolentivec), an Orphan Drug and Breakthrough Therapy from Bluebird Bio, corrects the defect causing beta thalassemia, a blood disorder that causes life-threatening anaemia.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    7. LentiGlobin TDT – a gene therapy first for Europe. Gene therapy company Bluebird Bio is on course to gain approval for its first product this year – and Europe is expected to ... Bluebird says its decision to file in Europe first was in part

  • Regeneron and Bluebird sign $100m cell therapies deal Regeneron and Bluebird sign $100m cell therapies deal

    Six targets chosen from TCR and other cell therapy platforms. ‘Big biotech’ Regeneron and cell and gene therapy specialists Bluebird Bio have unveiled a new collaboration which gives both greater presence ... The collaboration with Regeneron

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    Bluebird Bio's chief executive Nick Leschly. Cell and gene therapy made the transition from an interesting but unproven science to medical reality in 2017, with two ‘living medicine’ CAR-T ... The next company to play its hand in this biotech-led

  • Deal Watch September 2016 Deal Watch September 2016

    The lead programme EM801 is a T cell bispecific antibody targeting B-cell maturation antigen (BCMA), which s considered to be complementary to Bluebird bio's CAR T cell therapies targeting ... 1, 695. Medigene /Bluebird bio. Licence. Development and

More from intelligence
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change
...

Infographics